Provided by Tiger Trade Technology Pte. Ltd.

OPUS GENETICS INC

5.73
+1.3932.03%
Post-market: 6.070.3399+5.93%19:59 EDT
Volume:54.32M
Turnover:331.75M
Market Cap:476.71M
PE:-4.43
High:7.07
Open:5.31
Low:5.31
Close:4.34
52wk High:7.07
52wk Low:1.32
Shares:83.20M
Float Shares:65.21M
Volume Ratio:18.35
T/O Rate:83.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2925
EPS(LYR):-0.8000
ROE:-4796.52%
ROA:-48.06%
PB:-36.71
PE(LYR):-7.16

Loading ...

Opus Genetics up over 32%, on Track for Largest Percent Increase Since February 2020

Dow Jones
·
13 hours ago

Opus Genetics Reach 52-Week High on Clinical Trial, FDA Progress

Dow Jones
·
13 hours ago

Top Midday Gainers

MT Newswires Live
·
13 hours ago

U.S. Stocks on the MOVE-Apple, Omnicom, Jersey Mike's Subs

Reuters
·
13 hours ago

Opus Genetics price target raised to $16 from $13 at Chardan

TIPRANKS
·
14 hours ago

Wedbush Raises Opus Genetics Price Target to $13 From $10, Maintains Outperform Rating

MT Newswires Live
·
15 hours ago

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)

TIPRANKS
·
Yesterday

Opus Genetics Price Target Maintained with a $13.00/Share by Chardan Capital

Dow Jones
·
Yesterday

Opus Genetics Reports Positive Phase 1/2 Low-Dose Cohort 1 Data for OPGx-BEST1 Gene Therapy in BEST1 Retinal Disease

Reuters
·
Yesterday

Opus Genetics - FDA Aligns on ≥3 Decibels Microperimetry Improvement as Potential Pivotal Endpoint

THOMSON REUTERS
·
Yesterday

Opus Genetics - Opgx-Best1 Demonstrates Favorable Safety with no Serious Adverse Events or Dose-Limiting Toxicities

THOMSON REUTERS
·
Yesterday

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of Opgx-Best1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

THOMSON REUTERS
·
Yesterday

Opus Genetics - Cohort 2 Dosing to Complete in Q4 2026, Topline Data Expected Q2 2027

THOMSON REUTERS
·
Yesterday

Opus Genetics - All Five Participants Show Clinically Meaningful Improvement in Visual Function

THOMSON REUTERS
·
Yesterday

Opus Genetics to Report Phase 1/2 Cohort 1 Topline Data for OPGx-BEST1 Gene Therapy Sept. 9 Webcast

Reuters
·
Sep 02

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

THOMSON REUTERS
·
Aug 20

Longeveron - Marie Washburn Steps Down as CFO, Returns to Corporate Controller Role

THOMSON REUTERS
·
Aug 20

Opus Genetics Grants Options for 310,000 Shares Under Inducement Plan

Reuters
·
Aug 20

Opus Genetics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 20

Opus Genetics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11